Innovation and commercialisation in the biopharmaceutical industry: Creating and capturing value

Innovation and Commercialisation in the Biopharmaceutical Industry: Creating and Capturing Value

Volumn , Issue , 2010, Pages

  Rasmussen, Bruce ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858705868     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (328)

1. Achilladelis, B. 1999, 'Innovation in the Pharmaceutical Industry', in R. Landau, B. Achilladelis and A. Scriabine (eds), Pharmaceutical Innovation: Revolutionising Human Health, Chemical Heritage Foundation, Philadelphia.
2. Affymetrix Inc. 1996, Prospectus, US Securities and Exchange Commission, Washington DC.
3. Affymetrix Inc. 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
4. Affymetrix Inc. 2009, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
5. Afuah, A. and Tucci, C. 2001, Internet Business Models and Strategies: Text and Cases, McGraw- Hill Irwin, London.
6. Aghion, P. and Tirole, J. 1994, 'The management of innovation', Quarterly Journal of Economics, vol. 109, no. 4, pp. 1185-1207.
7. Alexion Pharmaceuticals Inc. 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
8. Alexion Pharmaceuticals Inc. 2009, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
9. American Chemical Society (ACS) 2000, The Pharmaceutical Century: Ten Decades of Drug Discovery, ACS, Washington, DC
10. Amgen Inc. 2002, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
11. Amgen Inc. 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
12. Amgen Inc. 2009, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
13. Amit, R. and Schoemaker, P. 1993, 'Strategic assets and organizational rent', Strategic Management Journal, vol. 14, pp. 33-46.
14. Amit, R. and Zott, C. 2001, 'Value creation in e- business', Strategic Management Journal, vol. 22, no. 6/7, pp. 493-520.
15. Arora, A. and Gambardella, A. 1990, 'Complementarity and external linkages in biotechnology: The strategies of large firms in biotechnology', Journal of Industrial Economics, vol. 38, no. 4, pp. 361-379.
16. Arora, A., Fosfuri, A. and Gambardella, A. 2001, Markets for Technology: The Economics of Innovation and Corporate Strategy, MIT Press, Cambridge, Mass.
17. Arora, A., Gambardella, A., Magazzini, L. and Pammolli, F. 2007, 'A Breath of Fresh Air Firm types, scale, scope and selection effects in drug development', submission draft to Management Science, (published in 2009, vol. 55, no. 10, pp. 1638-1653).
18. AstraZeneca 2001, 'AstraZeneca Approach to E- Business', presentation to analysts, New York
19. Bagchi- Sen, S., Lawton Smith, H. and Hall, L. 2004, 'The US biotechnology industry: Policy and practice', Environment and Planning C: Government and Policy, vol. 22, pp. 199-216.
20. Barney, J.R. 1986, 'Strategic factor markets: Expectations, luck and business strategy', Management Science, vol. 32, pp. 1231-1241.
21. Barney, J.R. 1991, 'Firm resources and sustained competitive advantage', Journal of Management, vol. 17, pp. 99-120.
22. Baumol, W. and Willig, R. 1981, 'Fixed costs, sunk costs, entry barriers and sustainability of monopoly', Quarterly Journal of Economics, vol. 95, pp. 405-431.
23. Beeley, N. and Berger, A. 2000, 'A revolution in drug discovery', BMJ, vol. 321, pp. 581-582.
24. Berndt, E.R., Bui, L., Reiley, D.R. and Urban, G.L. 2001, 'Information, marketing and pricing in the US antiulcer drug market', Information, Educating and Marketing in Health Care, vol. 85, no. 2, pp. 100-105.
25. Biogen IDEC Inc. 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
26. Biogen IDEC Inc. 2009, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
27. BioLateral and the Bioinformatics Industry Opportunity Taskforce 2002, 'Bioinformatics: Issues and Opportunities for Australia, Emerging Industries', Occasional Paper No. 15, Department of Industry, Tourism and Resources, Canberra, available at: http://bioinformatics.org.au/files/documents/biot-report-final.pdf (accessed April 2002).
28. Blumberg, D. and Perrone, F. 2001, 'How Much are Marketing and Sales Capabilities Really Worth A European Study on How the Capabilities Drive Performance', Accenture, www.acenture.com.
29. Brealey, R.A. and Myers, S.C. 2003, Principles of Corporate Finance, McGraw Hill, New York.
30. Bresnahan, T.F. and Trajtenberg, M. 1995, 'General purpose technologies: "Engines of growth"', Journal of Econometrics, vol. 65, pp. 83-108.
31. Burgleman, R., Maidique, M. and Wheelwright, S. 2001, Strategic Management of Technology and Innovation, McGraw Hill, Boston.
32. Cambridge Antibody Technology Group PLC 2003, 'Home', available at: http://www.cambridgeantibody.com/ (accessed 25 March 2008).
33. Cambridge Antibody Technology Group PLC 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC
34. Cambridge Antibody Technology Group PLC 2009, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC
35. Cambridge Antibody Technology Group 2006, Form 20- F, US Securities and Exchange Commission, Washington, DC
36. Carlsson, B. and Eliasson, G. 1994, 'The nature and importance of economic competence', Industrial and Corporate Change, vol. 3, no. 1, pp. 687-711.
37. Carlsson, B. and Stankiewicz, R. 1991, 'On the nature, function and composition of technological systems', Journal of Evolutionary Economics, vol. 1, pp. 93-118.
38. Casper S. 2000, 'Institutional adaptiveness, technology policy, and the diffusion of new business models: The case of German biotechnology', Organization Studies, vol. 21, pp. 887-914.
39. Casper, S. and Kettler, H. 2001, 'National institutional frameworks and the hybridization of entrepreneurial business models: The German and UK biotechnology sectors', Industry and Innovation, vol. 8, no. 1, pp. 5-30.
40. Casper, S. and Matraves, C. 2003, 'Institutional frameworks and innovation in the German and UK pharmaceutical industry', Research Policy, vol. 32, pp. 1865-1879.
41. Casper, S. and Murray, F. 2003, 'Examining the marketplace for ideas: How local are European biotechnology clusters', in M. McKelvey and J. Hageman (eds), Industrial Dynamics in European Biotechnology, Edward Elgar, London.
42. Casper, S. and Whitley, R. 2004, 'Managing competences in entrepreneurial technology firms: A comparative institutional analysis of Germany, Sweden and the UK', Research Policy, vol. 33, pp. 89-106.
43. Centre for Drug Evaluation and Research (CDER) 2007, 'CDER New Molecular Entity (NME) Drug and New Biologic Approvals in Calendar Year 2007', Food and Drug Administration, Washington DC, available at: http://www.fda.gov/cder/rdmt/InternetNME07.htm (accessed 26 May 2008).
44. Chandler, A. 1977, The Visible Hand: The Managerial Revolution in American Business, Harvard University Press, Cambridge, Mass.
45. Chandler, A. 1990, Scale and Scope: The Dynamics of Industrial Capitalism, Harvard University Press, Cambridge, Mass.
46. Chandler, A. 2005, Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries, Harvard University Press, Cambridge, Mass.
47. Chesbrough, H. 2003, Open Innovation: The New Imperative for Creating and Profiting from Technology, Harvard University Press, Cambridge, Mass.
48. Chesbrough, H. 2006, 'Open innovation: A new paradigm for understanding industrial innovation', in H. Chesbrough, W. Vanhaverbeke and J. West (eds), Open Innovation: Researching a New Paradigm, Harvard University Press, Cambridge, Mass.
49. Chesbrough, H. and Rosenbloom, R.S. 2002, 'The role of the business model in capturing value from innovation: Evidence from Xerox Corporation's technology spin- offcompanies', Industrial and Corporate Change, vol. 11, pp. 529-555.
50. Chesbrough, H., Vanhaverbeke, W. and West, J. (eds) 2006, Open Innovation: Researching a New Paradigm, Harvard University Press, Cambridge, Mass.
51. Christensen, C.M. and Rosenbloom, R.S. 1995, 'Explaining the attacker's advantage: Technological paradigms, organizational dynamics and the value network', Research Policy, vol. 24, no. 2, pp. 233-257.
52. Christensen, J.F. 2006, 'Whither core competency for the large corporation in an open innovation world', in H. Chesbrough, W. Vanhaverbeke and J. West (eds), Open Innovation: Researching a New Paradigm, Harvard University Press, Cambridge, Mass.
53. Coase, R.H. 1937, 'The nature of the firm', 4 Economica (new series), 386.
54. Cockburn, I. 2004, 'The changing structure of the pharmaceutical industry', Health Affairs, vol. 23, no. 1, pp. 10-22.
55. Cockburn, I. 2005, 'State Street Meets the Human Genome Project: Intellectual Property and Bioinformatics', in R. Hahn (ed.), Intellectual Property Rights in Frontier Industries, AEI- Brookings Joint Centre for Regulatory Studies, Washington, DC.
56. Cockburn, I. and Griliches, Z. 1988, 'Industry effects and appropriability measures in the stock market's valuation of R&D and patents', American Economic Review, vol. 78, no. 2, pp. 419-423.
57. Cockburn, I. and Henderson, R. 2001, 'Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research', Journal of Health Economics, vol. 20, no. 6, pp. 1033-1057.
58. Cockburn, I., Henderson, R. and Stern, S. 2000, 'Untangling the origins of competitive advantage', Strategic Management Journal, vol. 21, pp. 1123-1145.
59. Cohen, S., Chang, A., Boyer, H. and Helling, R. 1973, 'Construction of biologically functional bacterial plasmids in vitro', Proceedings of the National Academy of Science, vol. 70, pp. 3240-3244.
60. Cohen, W.M. and Levinthal, D.A. 1990, 'Absorptive capacity: A new 294 Innovation and commercialisation in the biopharmaceutical industry perspective on learning and innovation', Administrative Science Quarterly, vol. 35, pp. 128-152.
61. Congressional Budget Office (CBO) 2008, 'Cost Estimate: S1695: Biologics Price Competition and Innovation Act of 2007: As Ordered Reported by US Senate Committee on Health, Education, Labor and Pensions on June 2007', 25 June 2008, CBO, Washington, DC
62. Conner, K.R. 1991, 'A historical comparison of resource- based theory and five schools of thought within industrial organization economics: Do we have a new theory of the firm', Journal of Management, vol. 17, pp. 121-154.
63. Cooke, P. 2001, 'Biotechnology clusters in the UK: Lessons from localisation in the commercialisation of science', Small Business Economics, vol. 16, nos. 1-2, pp. 43-59.
64. Cooke, P. 2003, 'The evolution of biotechnology in three continents: Schumpeterian or Penrosian', European Planning Studies, vol. 11, no. 7, pp.757-764.
65. Cooke, P. 2004a, 'The molecular biology revolution and the rise of bioscience megacentres in North America and Europe', Environment and Planning C: Government and Policy, vol. 22, pp. 161-177.
66. Cooke, P. 2004b, 'Regional knowledge capabilities, embeddedness of firms and industry organisation: Bioscience metacentres and economic geography', European Planning Studies, vol. 12, no. 5, pp. 625-641.
67. Cooke, P. 2006a, 'Global bioregional networks: A new economic geography of bioscientific knowledge', European Planning Studies, vol. 14, no. 9, pp.1265-1285.
68. Cooke, P. 2006b, 'Global bioregions: Knowledge domains, capabilities and innovation system networks', Industry and Innovation, vol. 13, no. 4, pp. 437-458.
69. Crepon, B., Duguet, E. and Mairesse, J. 1998, 'Research innovation and productivity: An econometric analysis at the firm level', Journal of Innovation and New Technologies, vol. 7, pp. 115-158.
70. CSIRO 1994, CSIRO Annual Report 1994, Canberra
71. CSIRO 2001, CSIRO Annual Report 2001, Canberra
72. Curagen Corporation 1998, Prospectus, US Securities and Exchange Commission, Washington, DC
73. Curagen Corporation 2005, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC
74. Danzon, P., Nicholson, S. and Pereira, N. 2005, 'Productivity in pharmaceutical- biotechnology R&D: the role of experience and alliances', Journal of Health Economics, vol. 24, pp. 317-339.
75. De Carolis, D. and Deeds, D. 1999, 'The impact of stocks and flows of organizational knowledge on firm performance: An empirical evaluationof the biotechnology industry', Strategic Management Journal, vol. 20, pp. 953-968.
76. Deeds, D.L., De Carolis, D. and Coombs, J. 1999, 'Dynamic capabilities and new product development in high technology ventures: An empirical analysis of new biotechnology firms', Journal of Business Venturing, vol. 15, pp. 211-229.
77. Degami, S. and Van Brunt, J. 2003, 'Financial snapshot for December 2002: Down, but not out', Signals: The Online Magazine of Biotechnology Industry Analysis, January 2, available at: http://www.signalsmag.com/signalsmag.nsf/657b06742b5748e888256570005cba0 1/2488575d6afc884388256ca2006d9af6OpenDocument (accessed May 2008).
78. Degami, S. and Van Brunt, J. 2006, 'Financial snapshot for December 2005: Smaller stocks need to catch up', Signals: The Online Magazine of Biotechnology Industry Analysis, 18 January, available at: http://www.signalsmag.com/signalsmag.nsf/657b06742b5748e888256570005cba0 1/5de058858447e0f5882570f9000668e3OpenDocument (accessed May 2008).
79. Degami, S. and Van Brunt, J. 2009, 'Financial snapshot for December 2008: No relief in sight', Signals: The Online Magazine of Biotechnology Industry Analysis, 6 February, available at: http://www.signalsmag.com/signalsmag.nsf/0/11CE1B31D0C8DE92882575540078C C5F (accessed March 2009).
80. Deirickx, I. and Cool, K. 1989, 'Asset stock accumulation and sustainability of competitive advantage', Management Science, vol. 35, no. 12, pp. 1504-1511.
81. Demsetz, H. 1991, 'The theory of the firm revisited', in O.E. Williamson and S.G. Winter (eds), The Nature of the Firm, Oxford University Press, New York, pp. 159-178.
82. Dendritic Nanotechnologies Inc (DNT) 2005, 'Dendritic Nano-Technologies announces new low- cost family of precision nanostructures', press release, 18 May
83. Department of Education, Science and Training (DEST), 2003, Mapping Australian Science and Innovation: Main Report, Canberra, available at: http://www.dest.gov.au/mapping/ (accessed May 2008).
84. Dewer, R.D. and Dutton, J.E. 1986, 'The adoption of radical and incremental innovations: An empirical analysis', Management Science, vol. 32, pp. 1422-1433.
85. Dierickx, I. and Cool, K. 1989, 'Asset stock accumulation and sustainability of competitive advantage', Management Science, vol. 35, pp. 1504-1511.
86. DiMasi, J.A. and Grabowski, H.G. 2006, 'The cost of biopharmaceuticalR&D: Is biotech different', Tufts Center for the Study of Drug Development, Tufts University, Boston, Mass.
87. DiMasi, J.A. and Grabowski, H.G. 2007, 'The cost of biopharmaceutical R&D: Is biotech different', Managerial and Decision Economics, vol. 28, nos. 4-5, pp. 469-479.
88. DiMasi, J.A., Hansen, R. and Grabowski, H.G. 2003, 'The price of innovation: New estimates of drug development costs', Journal of Health Economics, vol. 22, pp. 151-185.
89. DiMasi, J.A., Hansen, R., Grabowski, H.G. and Lasagna, L. 1991, Cost of innovation in the pharmaceutical industry', Journal of Health Economics, vol. 10, pp. 107-142.
90. Discovery Partners International Inc. (DPI) 2000, Propectus, US Securities and Exchange Commission, Washington, DC.
91. Discovery Partners International Inc. (DPI) 2005, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
92. Dosi, G. 1982, 'Technological paradigms and technological trajectories: A suggested interpretation of the determinants and directors of technical change', Research Policy, vol. 11, pp. 147-162.
93. Drews, J. and Ryser, S.T. 1996, 'An innovative deficit in the pharmaceutical industry', Drug Information Journal, vol. 30, pp. 97-108.
94. Dunning, J. 1995, 'Reappraising the eclectic paradigm in an age of alliance capitalism', Journal of International Business Studies, vol. 26, no. 3, pp. 461-491.
95. Dyer, J. and Singh, H. 1998, 'The relational view: Cooperative strategy and sources of interorganizational competitive advantage', Academy of Management Review, vol. 23, no. 4, pp. 660-679.
96. Eliasson, G. 2000, 'The industrial potential of biotechnology: A competence bloc analysis', in J. De La Mothe and J. Noisi (eds), The Economic and Social Dynamics of Biotechnology, Springer, Heidelberg.
97. Ernst and Young 2005, Beyond Borders: Global Biotechnology Report 2005, Sydney
98. Ettlie, J.E., Bridges, W.P. and O'Keefe, R.D. 1984, 'Organization strategy and structural difference for radical versus incremental innovation', Management Science, vol. 30, pp. 682-695.
99. European Commission 2004, Communication from the Commission: Towards a European Strategy for Nanotechnology, COM(2004) 338, Brussels
100. European Commission 2005, Biotechnology 2020: From the Transparent Cell to the Custom- Designed Process, Brussels, available at: ftp://ftp.cordis.europa.eu/pub/food/docs/biotech_2020.pdf (accessed October 2008).
101. Food and Drug Administration (FDA) 2008a, 'CDER New Molecular Entity (NME) Drug and New Biologic Approvals in Calendar Year 2007', Washington DC, available at http://www.fda.gov/cder/rdmt/InternetNME07.htm (accessed 14 June 2008).
102. FDA 2008b, Drugs@FDA Data Files, United States Food and Drug Administration, at http://www.fda.gov/cder/drugsatfda/datafiles/default.htm (accessed 14 June 2008).
103. Feng, H., Froud, J., Johan, S., Halsma, C. and Williams, K. 2001, 'A new business model: The capital market and the new economy', Economy and Society, vol. 30, no. 4, pp. 467-503.
104. Fisken, J. and Rutherford, J. 2002, 'Business models and investment trends in the biotechnology industry in Europe', Journal of Commercial Biotechnology, vol. 8, no. 3, pp. 191-199.
105. Foss, N.J. 1996, 'Knowledge- based approaches to the theory of the firm: Some critical comments', Organization Science, vol. 78, pp. 470-476.
106. Freeman C. 1987, Technology Policy and Economic Performance: Lessons from Japan, Pinter, London.
107. Galambos, L. and Sewell, J.E. 1995, Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme and Mulford, 1895-1995, Cambridge University Press, New York.
108. Galambos, L. and Sturchio, J. 1998, 'Pharmaceutical firms and the transition to biotechnology: A study in strategic innovation', Business History Review, vol. 72, pp. 250-278.
109. Gambardella, A. 1995, Science and Innovation: The US Pharmaceutical Industry During the 1980s, Cambridge University Press, New York.
110. Gambardella, A., Orsenigo, L. and Pammolli, F. 2000, 'Global Competitiveness in Pharmaceuticals: A European Perspective', Report prepared for the Enterprise Directorate General of the European Commission, Luxembourg.
111. Gans, J.S. and Stern, S. 2003, 'The product market and the "market for ideas": Commercialization strategies for technology entrepreneurs', Research Policy, vol. 32, pp. 333-350.
112. Garnsey, E. and Leong, Y. 2008, 'Combining resource- based and evolutionary theory to explain the genesis of bio- networks', Industry and Innovation, vol. 15, no. 6, pp. 669-686.
113. George, P. and Perrone, F. 2001, 'How Much are Marketing and Sales Capabilities Really Worth What Every Pharmaceutical Executive Should Know, the US Study', Accenture, available at: www.acenture. com (accessed 31 August 2009).
114. Golec, J. and Vernon, J. 2007, 'Financial Risk in the Biotechnology Industry', NBER Working Paper 13604, National Bureau of Economic Research, Cambridge, Mass.
115. Gomes- Casseres, B. 1996, The Alliance Revolution: The New Shape of Business Rivalry, Harvard University Press, Cambridge, Mass.
116. Gosse, M.E. and Manocchia, M. 1996, 'The first bio- pharmaceuticals approved in the US, 1980-1994', Drug Information Journal, vol. 30, pp. 991-1001.
117. Grabowski, H. 2002, 'Patents and new product development in the pharmaceutical and biotechnology industries', Duke University, Durham, North Carolina.
118. Grabowski, H. and Vernon, J. 1994a, 'Innovation and structural change in pharmaceuticals and biotechnology', Industrial and Corporate Change, vol. 3, pp. 435-449.
119. Grabowski, H. and Vernon, J. 1994b, 'Returns to R&D on new drug introductions in the 1980s', Journal of Health Economics, vol. 13, pp. 383-406.
120. Grabowski, H. and Vernon, J. 2001, 'Pressures from the demand side: Changing market dynamics and industrial structure', in H. Kettler (ed.), Consolidation and Competition in the Pharmaceutical Industry, based on papers delivered at the OHE Conference, London, 16 October 2000, Office of Health Economics.
121. Grabowski, H., Ridley, D. and Schulman, K. 2006, 'Entry and competition in generic biologicals', mimeo, Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, North Carolina.
122. Granberg, A. and Stankiewicz, R. 2002, 'Biotechnology and the transformation of the pharmaceutical value chain and innovation system', paper presented at the Medicon Valley BioConference, Medicon Valley Academy, Copenhagen, 8-10 October.
123. Granstrand, O., Patel, P. and Pavitt, K. 1997, 'Multi- technology corporations: Why they have "distributed" rather than "distinctive" core competencies', California Management Review, vol. 39, pp. 8-25.
124. Grant, R.M. 1991, 'The resource- based theory of competitive advantage: Implications for strategy formulation', California Management Review, vol. 33, pp. 114-135.
125. Griffith, T. 2003, 'Biotech merger draws cool reception: Analysts see risk of slowing growth in Biogen- IDEC combo', 4 June, available at: http://www.CBS.Marketwatch.com.
126. Griliches, Z. 1979, 'Issues in assessing the contribution of R&D to productivity growth', The Bell Journal of Economics, vol. 10, pp. 92-116.
127. Griliches, Z. 1981, 'Market value, R&D and patents', Economic Letters, vol. 7, pp. 183-187.
128. Griliches, Z. 1986, 'Productivity, R&D and basic research at the firm level in the 1970s', American Economic Review, vol. 76, no. 1, pp. 141-154.
129. Griliches, Z. 1990, 'Patent statistics and economic indicators: A survey', Journal of Economic Literature, vol. 28, pp. 1661-1707.
130. Griliches, Z. and Lichtenberg, F. 1982, 'R&D and Productivity at the Industry Level: Is There Still a Relationship', NBER Working Paper No. 850, National Bureau of Economic Research, Cambridge, Mass.
131. Grossman, S. and Hart, O. 1986, 'The costs and benefits of ownership: A theory of vertical and lateral integration', Journal of Political Economy, vol. 94, no. 4, pp. 691-719.
132. Guedji, I. 2005, 'Ownership vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D', Mimeo, University of Texas at Austin.
133. Guedj, I. and Scharfstein, D. 2004, 'Organisational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms', NBER Working Paper No. 10933, National Bureau of Economic Research, Cambridge, Mass.
134. Gulati, R. 1998, 'Alliances and networks', Strategic Management Journal, vol. 19, pp. 293-317.
135. Hagedoorn, J. 1993, 'Understanding the rationale of strategic technology partnering: Inter- organizational modes of cooperation and sectoral differences', Strategic Management Journal, vol. 14, pp. 371-385.
136. Hagedoorn, J., Link, A. and Vonortas, N. 2000, 'Research partnerships', Research Policy, vol. 29, pp. 567-586.
137. Hall, B.H. 1993, 'The stock market's valuation of R&D investment during the 1980s', American Economic Review, vol. 83, no. 2, pp. 259-264.
138. Hall, B.H., Jaffe, A. and Trajtenberg, M. 2000, 'Market value and patent citations: A first look', NBER Working Paper No. 7741, National Bureau of Economic Research, Cambridge, Mass.
139. Hansen, R.W. 1980, 'Pharmaceutical Development Costs by Therapeutic Categories', University of Rochester Graduate School of Management Working Paper No. GPB- 80-6, March.
140. Harhoff, D., Narin, G., Scherer, F.M. and Vopel, K. 1999, 'Citation frequency and the value of patented inventions', The Review of Economics and Statistics, vol. 81, pp. 511-515.
141. Harrison, R. 2003, 'Protecting innovation in bioinformatics and in- silico biology', Biodrugs, vol. 17, pp. 227-231.
142. Hart, O. and Moore, J. 1990, 'Property rights and the nature of the firm', Journal of Political Economy, vol. 98, no. 6, pp. 1119-1158.
143. Hart, S.J. and Baker, M.J. 1994, 'The multiple convergent processing model of new product development', International Marketing Review, vol. 11, no. 1, pp. 77-92.
144. Hedman, J. and Kalling, T. 2002, IT and Business Models: Concepts and Theories, Copenhagen Business School Press, Copenhagen.
145. Heller, M. and Eisenberg, R. 1988, 'Can patents deter innovation The anticommons in biomedical research', Science, vol. 280, pp. 698-701.
146. Helpman, E. (ed.) 1998, General Purpose Technologies and Economic Growth, MIT Press, Cambridge, MA.
147. Henderson, R. and Cockburn, I. 1994, 'Measuring competence Exploring firm effects in pharmaceutical research', Strategic Management Journal, vol. 15, pp. 63-84.
148. Henderson, R. and Cockburn, I. 1996, 'Scale, scope and spillovers: The determinants of research productivity in drug discovery', Rand Journal of Economics, vol. 27, no. 1, pp. 32-59.
149. Henderson, R. and Clark, K. 1990, 'Architectural innovation: The reconfiguration of existing product technologies and the failure of established firms', Administrative Science Quarterly, vol. 35, pp. 9-30.
150. Herpin, T., Karuso, H. and Foley, J. 2005, 'Australian biotech companies: Navigating the maze', Journal of Commercial Biotechnology, vol. 11, no. 2, pp. 111-120.
151. Higgins, M.J. and Rodriguez, D. 2006, 'The outsourcing of R&D through acquisitions in the pharmaceutical industry', Journal of Financial Economics, vol. 80, pp. 351-383.
152. Hine, D. and Kapeleris, J. 2006, Innovation and Entrepreneurship in Bio tech nology: An International Perspective: Concepts and Theories, Edward Elgar, Cheltenham, UK and Northampton, MA, USA.
153. Hobday, M. 1998, 'Product complexity, innovation and industrial organisation', Research Policy, vol. 26, pp. 689-710.
154. Hobday, M., Rush, H. and Tidd, J. 2000, 'Innovation in complex products and systems', Research Policy, vol. 29, pp. 793-804.
155. Houghton, J. and Rasmussen, B. 2002, 'The Convergence of Information Technology and Biotechnology: Bioinformatics Developments and Implications', CSES Working Paper No. 20-1, CSES, Victoria University, Melbourne.
156. Human Genome Sciences Inc. 2002, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
157. Human Genome Sciences Inc. 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
158. Human Genome Sciences Inc. 2009, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
159. ICOS Corporation 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC
160. ImClone Systems Inc. 2001, 'Letter to Shareholders', in Annual Report 2001, pp. 2-6, available at: http://phx.corporate-ir.net/phoenix.zhtmlc=97689&p=irol-reportsAnnua l (accessed March 2008).
161. ImClone Systems 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC
162. Incyte Corporation 1996, Prospectus, US Securities and Exchange Commission, Washington, DC
163. Incyte Corporation 2006, Form 10- K, US Securities and Exchange Commission, Washington, DC
164. In- PharmaTechnologist.com 2005, 'Dow spins out dendrimer portfolio to nanotech firm', In- PharmaTechnologist.com, 26 January, available at: http://www.in-pharmatechnologist.com/news/ng.aspid=57592 (accessed November 2008).
165. Jackson, R.A. 2005, 'Starpharma raises another AUD $15M to support VivaGel', NanoBiotech News, 30 November, p. 9.
166. Jaffe, A. 1999, 'The US Patent System in Transition: Policy Innovation and the Innovation Process', NBER Working Paper No. 7280, National Bureau of Economic Research, Cambridge, Mass.
167. Jaffe, A. and Lerner, J. 2004, How Our Broken Patent System is Endangering Innovation and Progress and What to Do About It, Princeton University Press, Princeton, NJ.
168. Jovanovic, B. and Rousseau, P.L. 2003, 'General Purpose Technologies', Department of Economics, New York University.
169. Kang, N.- H. and Sakai, K. 2000, 'International Strategic Alliances: Their Role in Industrial Globalisation', STI Working Paper No. 200/5, Directorate for Science, Technology and Industry, OCED, Paris.
170. Kay, J. 2001, 'Changes in market structure: The economic issues', in H. Kettler (ed.), Consolidation and Competition in the Pharmaceutical Industry, Office of Health Economics (OHE), London.
171. Kenney, M. 1986, Biotechnology: The University-Industrial Complex, Yale University Press, New Haven, CT.
172. Kittredge, A. 2005, 'A shrinking target: Clinical trials are taking longer and costing more, as competition from patients heats up', The Scientist, vol. 19, no. 7, pp. 46.
173. Klaes, M. and Stent, E.M. 2005, 'A conceptual history of the emergence of bounded reality', History of Political Economy, vol. 37, no. 1, pp. 27-59.
174. Klein, B., Crawford, R.G. and Alchian, A.A. 1978, 'Vertical integration, appropriable rents and the competitive contracting process', The Journal of Law and Economics, vol. 21, pp. 297-326.
175. Kogut, B. 1988, 'Joint ventures: Theoretical and empirical perspectives', Strategic Management Journal, vol. 9, pp. 319-332.
176. Kogut, B. and Zander, U. 1992, 'Knowledge of the firm, combinative capabilities and the replication of technology', Organization Science, vol. 3, no. 3, pp. 383-397.
177. Kogut, B. and Zander, U. 1993, 'Knowledge of the firm and the evolutionary theory of the multinational corporation', Journal of International Business Studies, 4th quarter, pp. 625-644.
178. Lähteenmäki, R. and Lawrence, S. 2006, 'Public biotechnology 2005: The numbers', Nature Biotechnology, vol. 24, no. 6, pp. 625-634.
179. Landau, R. 1999, 'Introduction', in R. Landau, B. Achilladelis and A. Scriabine (eds), Pharmaceutical Innovation: Revolutionising Human Health, Chemical Heritage Press, Philadelphia.
180. Langlois, R.N. 2003, 'The vanishing hand: The changing dynamics of industrial capitalism', Industrial and Corporate Change, vol. 12, pp. 351-385.
181. Lanjouw, J. and Schankerman, M. 2004, 'Patent quality and research productivity: Measuring innovation with multiple indicators', The Economic Journal, vol. 114, pp. 441-465.
182. Laursen, K. and Salter, A. 2006, 'Open innovation: The role of openness in explaining innovation performance among UK manufacturing firms', Strategic Management Journal, vol. 27, pp. 131-150.
183. Leader, B., Baca, Q. and Golan, D. 2008, 'Protein therapeutics: A summary and pharmacological classification', Nature Drug Discovery, vol. 7, January, pp. 21-39.
184. Lerner, J. 1994, 'Venture capitalists and the decision to go public', Journal of Financial Economics, vol. 35, no. 3, pp. 293-316.
185. Lerner, J. 1995, 'Venture capitalists and the oversight of private firms', Journal of Finance, vol. 50, no. 1, pp. 301-318.
186. Lerner, J. 2002, 'Patent Protection and Innovation over 150 Years', NBER Working Paper No. 8977, National Bureau of Economic Research, Cambridge, Mass.
187. Lerner, J. and Merges, R. 1998, 'The Control of Strategic Alliances: An Empirical Analysis of Biotechnology Collaborations', NBER Working Paper No. 6014, National Bureau of Economic Research, Cambridge, Mass.
188. Lichtenberg, F. 1996, 'The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality (HE PR)', NBER Working Paper No. 5418, National Bureau of Economic Research, Cambridge, Mass.
189. Lim, L.P.L., Garnsey, E. and Gregory, M. 2006, 'Product and process innovation in biopharmaceuticals: A new perspective on development', R&D Management, vol. 36, no. 1, pp. 27-36.
190. LION Bioscience AG 2002a, 'Business Model', available at: http://www.lionbioscience.com/company/business-model (accessed 25 March 2003).
191. LION Bioscience AG 2002b, 'R&D Report', in Annual Report 2002, Heidelberg, Germany
192. Lubik, S. and Garnsey, E. 2008, 'Commercialising nanotechnology innovations from university spin- out companies', Nanotechnology Perceptions, vol. 4, pp. 225-238.
193. Lundvall, B. 1992, National Systems of Innovation, Towards a Theory of Innovation and Interactive Learning, Pinter, London.
194. Lux Research 2005a, The Nanotech Intellectual Property Landscape, New York
195. Lux Research 2005b, 'Statement of Findings: The Nanotech IP Landscape', New York
196. Malerba, F. 2005, 'Sectoral systems of innovation: A framework for linking innovation to the knowledge base, structure and dynamics of sectors', Economics of Innovation and New Technology, vol. 14, nos. 1-2, pp. 63-82.
197. Malerba, F. and Orsenigo, L. 1990, 'Technological regimes and patterns of innovation: A theoretical and empirical investigation of the Italian case', in A. Heertje and M. Perlman (eds), Evolving Industries and Market Structures, University of Michigan Press, Ann Arbor.
198. Malerba, M. and Orsenigo, L. 1993, 'Technological regimes and firm behaviour', Industrial and Corporate Change, vol. 2, no. 45-71.
199. Malknight, T. 1999a, 'Eli Lilly, 1998 (A): Strategic challenges', 9-399-173, Harvard Business School Publications and IMD International, Boston.
200. Malknight, T. 1999b, 'Eli Lilly, 1998 (B): Emerging global organization', 9-399-174, Harvard Business School Publications and IMD International, Boston.
201. Margretta, J. 2002, 'Why business models matter', Harvard Business Online, January, available at: http://harvardbusinessonline.hbsp.harvard.edu/relay.jhtmlname=itemdetail &id=R0205F&referral=8636 (accessed March 2008).
202. Martin, B.R. and Salter, A. 1996, The Relationship between Publicly Funded Research and Economic Performance: A SPRU Review, Science Policy Research Unit, University of Sussex, Brighton.
203. Martin, B.R. and Tang, P. 2007, 'The Benefits from Publicly Funded Research', SEWPS Paper No. 161, Science and Technology Policy Research (SPRU), University of Sussex, Brighton.
204. Mathers, C.D. and Loncar, D. 2006, 'Projections of global mortality and burden of disease from 2002 to 2030', PLoS Medicine, vol. 3, no. 11, pp. 2011-2030.
205. McKelvey, M. 1996, Evolutionary Innovations: The Business of Technology, Oxford University Press, Oxford.
206. McKelvey, M., Rickne, A. and Laage- Hellman, J. 2004, 'Stylized facts about innovation processes in modern biotechnology', in M. McKelvey, J. Laage- Hellman and A. Rickne (eds), The Economic Dynamics of Modern Biotechnology, Edward Elgar, Cheltenham, UK and Northampton, MA, USA.
207. Mercer Management Consulting 2001, 'Where are the Next Profit Zones in Pharmaceuticals The Blockbuster Model will Begin to Yield Winners and Losers', Boston
208. Merck 2003, Annual Report 2003, New York
209. Millennium Pharmaceuticals Inc. 2002, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
210. Millennium Pharmaceuticals Inc. 2003, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
211. Mosakowski, E. and McKelvey, B. 1997, 'Predicting rent generation in competence- based competition', in A. Heene and R. Sanchez (eds), Competence- based Strategic Management, pp. 65-85, John Wiley, New York.
212. Mowery, D. 1983, 'The relationship between intrafirm and contractual forms of industrial research in American manufacturing, 1900-1940', Explorations in Economic History, vol. 20, pp. 351-374.
213. Myers, S.C. and Shyam- Sunder, L. 1995, 'Measuring pharmaceutical industry risk and the cost of capital', in R.B. Helms (ed.), Competitive Strategies in the Pharmaceutical Industry, American Enterprise Institute for Public Policy, Washington, DC.
214. NanoInvestorNews 2005, 'Dendritic NanoTechnologies, Dow and Starpharma sign major three- way deal to commercialize nanotechnology', 25 January, available at: http://www.dendrimercenter.org/images/downloads/DOWannouncement.pdf (accessed November 2008).
215. Narin, F., Noma, E. and Perry, R. 1987, 'Patents as indicators of corporate technological strength', Research Policy, vol. 16, pp. 143-155.
216. National Center for Biotechnology Information (NCBI) 2004, 'Microarrays: Chipping Away at the Mysteries of Science and Medicine', Bethesda, Maryland, available at: http://www.ncbi.nlm.nih.gov/About/primer/microarrays.html (accessed October 2008).
217. National Institutes of Health (NIH) 2007, 'National Roadmap for Medical Research: Nanomedicine, Overview', US Office of Portfolio Analysis and Strategic Initiatives, Maryland, available at: http://nihroadmap.nih.gov/nanomedicine (accessed 20 May 2008).
218. National Institutes of Health (NIH) 2008a, 'ERA Commons: Computer Retrieval of Information on Scientific Projects', available at: http://crisp.cit.nih.gov/ (accessed June 2008).
219. National Institutes of Health (NIH) 2008b, 'The NIH Almanac: Appropriations', US Department of Health and Human Services, Washington DC, available at: http://www.nih.gov/about/almanac/appropriations/part2.htm (accessed 20 May 2008).
220. National Nanotechnology Initiative 2007, 'The scale of things: Nanometersand more', available at: http://www.nano.gov/html/facts/The_scale_of_things.html (accessed 20 May 2008).
221. National Science Foundation (NSF) 2002, Converging Technologies for Improving Human Performance: Nanotechnology, Biotechnology, Information Technology and Cognitive Science, Arlington, Virginia
222. Nelson, R. 1993, National Innovation Systems: A Comparative Analysis, Oxford University Press, Oxford.
223. Nelson, R. and Winter, S. 1982, An Evolutionary Theory of Economic Change, Belknap Press, Cambridge, Mass.
224. Organisation for Economic Co-operation and Development (OECD) 1999, Managing National Innovation Systems, Paris
225. OECD 2000, International Strategic Alliances: Their Role in Industrial Globalisation, Paris
226. OECD 2001, Innovative Networks Co- operation in National Innovation Systems, Paris
227. OECD 2002, Dynamising National Innovations Systems, Paris
228. OECD 2005a, 'Statistical Definition of Biotechnology', OECD, Paris, available at: http://www.oecd.org/document/42/0,2340,en_2649_34537_1933994_1_1_1_1,00. html (accessed October 2008).
229. OECD 2005b, Oslo Manual: Guidelines for Collecting and Interpreting Innovation Data, Paris
230. Orsenigo, L. 1989, The Emergence of Biotechnology, Pinter, London.
231. Orsenigo, L., Pammolli, F. and Riccaboni, M. 2001, 'Technological change and network dynamics: Lessons from the pharmaceutical industry', Research Policy, vol. 30, pp. 485-508.
232. Owen- Smith, J. and Powell, W. 2004, 'Knowledge networks as channels and conduits: The effects of spillovers in the Boston biotechnology community', Organization Science, vol. 15, pp. 5-21.
233. PANBIO 2001, 'PANBIO joins the nanotechnology revolution', PANBIO Ltd, Brisbane, available at: http://www.panbio.com.au/download/nanotechnology%20revolution.pdf (accessed November 2008).
234. PAREXEL 2001, PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2001, Barnett International, Waltham, Mass
235. PAREXEL 2005, PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006, Barnett International, Waltham, Mass
236. PAREXEL 2006, PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2006/2007, Barnett International, Waltham, Mass
237. Patel, P. 2003, 'UK Performance in Biotechnology- related Innovation: An Analysis of Patent Data', Final Report prepared for the Assessment Unit of the UK Department of Trade and Industry, SPRU, University of Sussex, Brighton.
238. Penrose, E. 1951, The Economics of the International Patent System, John Hopkins University Press, Baltimore.
239. Perry, M.K. 1989, 'Vertical integration: Determinants and effects', in R. Schmalensee and R.D. Willig (eds), Handbook of Industrial Organization, North- Holland, Amsterdam.
240. Pharmaceutical Executive 2006, May, pp. 75-84, available at: http://pharmexec.findpharma.com/pharmexec/data/articlestandard//pharmexe c/302008/531367/article.pdf (accessed June 2008).
241. Pharmaceutical Research Manufacturers of America (PhRMA) 2006, Pharmaceutical Industry Profile 2006, Washington, DC
242. Pisano, G.P. 1991, 'The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry', Research Policy, vol. 20, pp. 237-249.
243. Pisano, G.P. 2006, Science Business: The Promise, the Reality and the Future of Biotech, Harvard Business School Press, Cambridge, Mass.
244. Porter, M. 1985, Technology and competitive advantage', The Journal of Business Strategy, vol. 5, no. 3, pp. 60-78.
245. Powell, W. 1998, 'Learning from collaboration: Knowledge and networks in the biotechnology and pharmaceutical industries', California Management Review, vol. 40, no. 3, pp. 228-240.
246. Powell, W., Koput, K. and Smith-Doerr, L. 1996, 'Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology', Administrative Science Quarterly, vol. 41, pp. 116-145.
247. Powell, W., Koput, K., Bowie, J. and Smith-Doerr, L. 2002, 'The spatial clustering of science and capital: Accounting for biotech firm-venture capital relationships', Regional Studies, vol. 36, no. 3, 291-305.
248. Prahalad, C. and Hamel, G. 1990, 'The core competence of the corporation', Harvard Business Review, May-June, 79-91.
249. PriceWaterhouseCoopers (PWC) 2007, 'Pharma 2020: The vision: Which path will you take', PWC, available at: http://www.pwc.com/extweb/pwcpublications.nsf/docid/91BF330647FFA4028525 72F2005ECC22 (accessed 20 August 2008).
250. Priem, R. and Butler, J. 2001, 'Is the resource- based "view" a useful perspective for strategic management research', Academy of Management Review, vol. 26, no. 1, pp. 22-40.
251. Qiagen 2003, Form 20- F: Annual and Transition Report of Foreign Private Issuers, US Securities and Exchange Commission, Washington, DC. Raff, J. 2005, 'Starpharma Holdings (ASX: SPL)', paper presented at the 2005 Emerging Growth Capital Annual Australian Biotechnology Expo, held in conjunction with the Australia Stock Exchange, Sydney, 9 August.
252. Rasmussen, B. 2004, 'Alliance Opportunities for Aus Biotechs',Pharmaceutical Industry Project Working Paper No. 23, June, CSES, Victoria University, Melbourne.
253. Rasmussen, B. 2006, 'Innovation and industry structure in the biomedical industry: Role of alliances', in B. Grewal and M. Kumnick (eds), Engaging the New World: Responses to the Knowledge Economy, Melbourne University Press, Melbourne.
254. Reichert, J.M. 2000, 'New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995-1999', Trends in Biotechnology, vol. 18, no. 9, pp. 364-369.
255. Reichert, J.M. 2001, 'Clinical development of therapeutic medicines: A biopharmaceutical versus pharmaceutical product comparison', Drug Information Journal, vol. 35, pp. 337-346.
256. Reichert, J.M. 2004, 'Biopharmaceutical approvals in the US increase', Regulatory Affairs Journal Pharma, vol. 15, no. 7, pp. 1-7.
257. Reichert, J.M. 2006, 'Trends in US approvals: New biopharmaceuticals and vaccines', Trends in Biotechnology, vol. 24, no. 7, pp. 293-298.
258. Reichert, J.M. and Paquette, C. 2003, 'Therapeutic recombinant proteins: Trends in US approvals', Current Opinion in Molecular Therapeutics, vol. 5, pp. 139-147.
259. Roco, M. and Bainbridge, W. (eds) 2005, Nanotechnology: Societal Implications, Maximizing Benefit for Humanity, Report of the National Nanotechnology Initiative Workshop, 3-5 December 2003, Subcommittee on Nanoscale Science, Engineering and Technology, National Science Foundation, Washington, DC.
260. Rosenberg, N. 1990, 'Why do firms do basic research (with their own money)', Department of Economics, Stanford University, Stanford, Calif.
261. Rothwell, R. 1994, 'Towards the fifth- generation innovation process', International Marketing Review, vol. 11, pp. 7-31.
262. Sampat, B.N. 2006, 'Patenting and US academic research in the 20th Century: The world before and after Bayh- Dole', Research Policy, vol. 35, pp. 772-789.
263. Saren, M.A. 1984, 'A classification and review of models of the intra- firm innovation process', R&D Management, vol. 14, no. 1, pp. 11-24.
264. Saxenian, A.L. 1994, Regional Advantage: Culture and Competition in Silicon Valley and Route 128, Harvard University Press, Cambridge, Mass.
265. Scherer, F.M. 1996, Industry Structure, Strategy and Public Policy, Harper Collins, New York.
266. Scherer, F.M. 2000, 'The pharmaceutical industry', in A.J. Culyer and J.P. Newhouse (eds), Handbook of Health Economics, Elsevier, Amsterdam.
267. Scriabine, A. 1999, 'Discovery and development of major drugs currently in use', in R. Landau, B. Achilladelis and A. Scriabine (eds), Pharmaceutical Innovation: Revolutionising Human Health, Chemical Heritage Press, Philadelphia.
268. Shan, W., Walker, G. and Kogut, B. 1994, 'Interfirm cooperation and startup innovation in the biotechnology industry', Strategic Management Journal, vol. 15, pp. 387-394.
269. Shane, S. 2001, 'Technological opportunities and new firm creation', Management Science, vol. 47, pp. 215-220.
270. Shapiro, C. and Varian, H. 1999, Information Rules: A Strategic Guide to the Network Economy, Harvard Business School Press, Boston, Mass.
271. Sharpe, W.F. 1964, 'Capital asset prices: A theory of market equilibrium under conditons of risk', Journal of Finance, vol. 19, no. 3, pp. 425-442.
272. Simon, H.A. 1955, 'A behavioural model of rational choice', Quarterly Journal of Economics, vol. 69, pp. 99-118.
273. Simon, H.A. 1957, Models of Man, John Wiley, New York.
274. Starpharma 1998, Starpharma Annual Report 1998, Melbourne
275. Starpharma 1999, Starpharma Prospectus 1999, Melbourne
276. Starpharma 2000a, Starpharma Prospectus 2000, Melbourne
277. Starpharma 2000b, Starpharma Annual Report 2000, Melbourne
278. Starpharma 2001, 'PANBIO to join Starpharma as investor in Dendritic Nanotechnologies Limited', press release, 10 September, Melbourne
279. Starpharma 2003, Starpharma Prospectus 2003, Melbourne
280. Starpharma 2004, 'Starpharma announces institutional share placement', press release, 18 March, Melbourne
281. Starpharma 2005a, 'Development of VivaGelTM significantly accelerated with $US20m funding from NIH', press release, 3 October, Melbourne
282. Starpharma 2005b, Starpharma Annual Report 2005, Melbourne
283. Starpharma 2005c, 'Starpharma secures full ownership of core technology', press release, 10 October, Melbourne
284. Starpharma 2007, 'CEO Presentation to Nanobusiness 2007 Conference', 16 April, Melbourne, available at: http://www.starpharma.com/data/070416%20Presentation%20Nanobusiness2007. pdf (accessed 12 May 2008).
285. Stein, J. 1997, 'Inter capital markets and the competition for corporate resources', The Journal of Finance, vol. LII, No. 1, March 1997, pp. 111-133.
286. Strategic Industry Research Foundation (SIRF) 1992, SIRF Annual Report 1992, Melbourne
287. Strategic Research Foundation (SRF) 1991, Annual Report 1990-91, Melbourne
288. Sutton, J. 1991, Sunk Costs and Market Structure: Price Competition, Advertising and the Evolution of Concentration, MIT Press, Cambridge, Mass.
289. Sutton, J., 1998, Technology and Market Structure: Theory and History, MIT Press, Cambridge, Mass.
290. Sweeny, K. 2002, 'Technology Trends in Drug Discovery and Development: Implications for the Development of the Pharmaceutical Industry in Australia', Pharmaceutical Industry Project Working Paper No. 3, March, CSES, Victoria University, Melbourne.
291. Teece, D.J. 1986, 'Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy', Research Policy, vol. 15, no. 6, pp. 285-305.
292. Teece, D.J. 2006, 'Reflections on "profiting from innovation"', Research Policy, vol. 35, pp. 1131-1146.
293. Teece, D.J. and Pisano, G. 1994, 'The dynamic capabilities of firms: An introduction', Industrial and Corporate Change, vol. 3, no. 3, pp. 537-556.
294. Teece, D.J., Pisano, G. and Shuen, A. 1997, 'Dynamic capabilities and strategic management', Strategic Management Journal, vol. 18, no. 7, pp. 509-533.
295. The Royal Society and The Royal Academy of Engineering 2004, 'Nanoscience and nanotechnologies: Opportunities and uncertainties', July, London, available at: http://www.nanotec.org.uk/finalReport.htm (accessed November 2008).
296. The Wall Street Transcript 2000, 'Dr Jonathan Rothberg - Curagen Corporation: CEO Interview', 17 September, available at: http://www.twst.com/ceos/crgn_sept17.html (accessed 29 May 2008).
297. Tollman, P., Guy, P., Altshuler, J., Flanagan, A. and Steiner, M. 2001, 'A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry', Boston Consulting Group, available at: http://www.bcg.com/impact_expertise/publications/files/eng_genomicsgenet ics_rep_11_01.pdf (accessed May 2008).
298. Toole, A. 2000, 'The Impact of Public Basic Research on Industrial Innovation: Evidence from the Pharmaceutical Industry', SIEPR Discussion Paper No. 00-07, Stanford Institute for Economic Policy Research, Stanford University, Stanford, Calif.
299. Trajtenberg, M., Henderson, R. and Jaffe, A. 1997, 'University versus corporate patents: A window on the basicness of invention', Economics of Innovation and New Technology, vol. 5, pp. 19-50.
300. Tripos Inc. 2007, Form 10- K: Annual Report, US Securities and Exchange Commission, Washington, DC.
301. Tufts Centre for the Study of Drug Development (CSDD) 2003,'Biopharmaceutical Development and Approval Times, 1982-2002', March, Tufts University, Boston
302. Tufts Center for the Study of Drug Development (CSDD) 2007, 'Outlook 2007', Tufts University, Boston
303. Uldrich, J. 2005, 'Starpharma: A "nano star" on the rise', NanoNovus, 17 March, available at: http://nanonovusblog.blogspot.com/2005/03/starpharma-nano-star-on-rise.h tml, (accessed November 2008).
304. US Department of Energy, Office of Science 2008, 'Genome Programs', Washington DC, available at: www.ornl.gov/hgmis (accessed 8 April 2008).
305. US Government Accountability Office (US GAO) 2006, 'New Drug Development: Science, Business, Regulatory and Intellectual Property Issues Cited as Hampering Drug Development Efforts', Report to Congressional Requestors, GAO- 07-49, Washington, DC
306. US Senate Committee on Health, Education, Labor and Pensions 2007, 'S1695: Biologics Price Competition and Innovation Act of 2007', Congressional Budget Office Cost Estimate, Washington, DC
307. Vanhaverbeke, W. and Cloodt, M. 2006, 'Open innovation in value networks', in H. Chesbrough, W. Vanhaverbeke and J. West (eds), Open Innovation: Researching a New Paradigm, Oxford University Press, Oxford, pp. 258-281.
308. Verlinder, M.C. 2000, 'Eli Lilly: The Evista Project', in Harvard Business School Press, From the Field: Inside Biotechnology and Pharmaceuticals, HBSP No. 4924, Harvard, Cambridge, Mass.
309. Vitale, M. 2004, 'Commercialising Australian Biotechnology', Australian Business Foundation, Sydney.
310. Wagner, V., Dullaart, A., Bock, A. and Zweck, A. 2006, 'The emerging. nanomedicine landscape', Nature Biotechnology, vol. 24, no. 10, pp. 1211-1217.
311. Walsh, G. 2002, 'Biopharmaceuticals and biotechnology medicines: An issue of nomenclature', European Journal of Pharmaceutical Sciences, vol. 15, pp. 135-138.
312. Walsh, G. 2003, Biopharmaceuticals: Biochemistry and Biotechnology, Wiley, Chichester.
313. Walsh, G. 2006, 'Biopharmaceutical benchmarks 2006', Nature Biotechnology, vol. 24, no. 7, pp. 769-776.
314. Walton, J. 2001, 'Investors' views on merger and acquisition, alliance and licensing activity in the pharmaceutical industry', in H. Kettler (ed.), Consolidation and Competition in the Pharmaceutical Industry, based on papers delivered at the OHE Conference, London, 16 October 2000, Office of Health Economics, London.
315. Weatherall, M. 1990, In Search of a Cure: A History of Pharmaceutical Discovery, Oxford University Press, Oxford.
316. Wernerfelt, B. 1984, 'A resource- based view of the firm', Strategic Management Journal, vol. 5, pp. 171-180.
317. Whelan, J. 2006, 'It's a small world: First generation nanomedicines are here and the arrival of polymer- based drug- delivery systems mean drugs can target specific points within a cell', Chemical and Industry, 20 February.
318. Wiggins, S.N. 1987, 'The cost of developing a new drug', Pharmaceutical Manufacturers Association, Washington, DC, June.
319. Williamson, O. 1971, 'The vertical integration of production: Market failure considerations', American Economic Review, vol. 61, no. 2, pp. 112-123.
320. Williamson, O. 1975, Markets and Hierarchies: Analysis and Antitrust Implications, The Free Press, New York.
321. Williamson, O. 1981, 'The modern corporation: Origins, evolution, attributes', Journal of Economic Literature, vol. 19, December, pp. 1537-1568.
322. Williamson, O. 1989, 'Transaction cost economics', in R. Schmalensee and R. Willig (eds), Handbook of Industrial Organization, North Holland, Amsterdam.
323. Williamson, O. 1999, 'Strategy research: Governance and competence perspectives', Strategic Management Journal, vol. 20, pp. 1087-1108.
324. Winter, S. 2000, 'Appropriating the gains from innovation', in G. Day and P. Schoemaker (eds), Wharton on Managing Emerging Technologies, John Wiley, New York.
325. Woodward, M. n.d. 'SNiPpetS and Bytes', Powerpoint presentation, US Patent and Trademark Office, Washington DC, available at: www.uspto.gov/web/patents/biochempharm/documents/snippets.pps (accessed June 2008).
326. Xenova Group PLC 2003, 'Home', at: www.xenova.co.uk (accessed 25 March 2003).
327. Zucker, L., Darby, M. and Armstrong, J. 1998a, 'Geographically localized knowledge: Spillovers or markets', Economic Inquiry, vol. 36, no. 1, pp. 65.
328. Zucker, L., Darby, M. and Brewer, M. 1998b, 'Intellectual human capital and the birth of US biotechnology enterprises', American Economic Review, vol. 88, no. 1, pp. 290-306.